Todos is a victim being a small company on OTC. The same news by any of the big pharmas would have generated $bil in stock appreciation. GC has to find a way to get on the big business networks to get the story out. I’m sure the company is working on it but I can also imagine interested parties who might be trying to stop it.

The next big PR opportunity is the admission of EUA application in the near future.